Natixis’s Impax Laboratories, Inc. IPXL Stock Holding History

Natixis’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-43,856	Closed	-$730K	–	1018
2017 Q4	$730K	Buy	43,856 +32,925	+301%	+$603K	0.01%	545
2017 Q3	$222K	Buy	+10,931	New	+$209K	﹤0.01%	1076

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCW Group Los Angeles, California $13.3B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Natixis's IPXL Position: Q1 2018 in Review

Natixis sold out of Impax Laboratories, Inc. (IPXL) in Q1 2018, closing a stake of 43,856 shares — an estimated $730K sold.

Natixis first reported a position in IPXL in Q3 2017 and held it in 2 quarters. The position peaked at $730K in Q4 2017. 188 funds tracked by Wall St. Rank hold IPXL as of Q1 2018.

Natixis reported no remaining Impax Laboratories, Inc. position as of Q1 2018 after selling out during the quarter.
Natixis sold 43,856 Impax Laboratories, Inc. shares in Q1 2018, an estimated $730K.
Natixis first reported a position in Impax Laboratories, Inc. in Q3 2017 and held it in 2 quarters.
Natixis's Impax Laboratories, Inc. position peaked at $730K in Q4 2017.
188 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2018.

Based on Natixis's 13F filing for Q1 2018, filed 15 May 2018.